Minfeng Chen

3.7k total citations · 2 hit papers
85 papers, 2.2k citations indexed

About

Minfeng Chen is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Minfeng Chen has authored 85 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 26 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Minfeng Chen's work include Bladder and Urothelial Cancer Treatments (16 papers), Urinary and Genital Oncology Studies (10 papers) and Prostate Cancer Treatment and Research (10 papers). Minfeng Chen is often cited by papers focused on Bladder and Urothelial Cancer Treatments (16 papers), Urinary and Genital Oncology Studies (10 papers) and Prostate Cancer Treatment and Research (10 papers). Minfeng Chen collaborates with scholars based in China, United States and Hong Kong. Minfeng Chen's co-authors include Dongmei Zhang, Wen‐Cai Ye, Lijuan Deng, Xiongbing Zu, Zhe‐Sheng Chen, Maohua Huang, Jinbo Chen, Lin Qi, Ming Qi and Huihui Zhang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Advanced Functional Materials.

In The Last Decade

Minfeng Chen

80 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

m6A modification: recent advances, anticancer targeted drug discovery and beyond

2022 252 citations Lijuan Deng, Minfeng Chen et al. Molecular Cancer profile →
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

2021 250 citations Peihua Liu, Wenbiao Ren et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minfeng Chen China	25	1.3k	607	465	439	280	85	2.2k
Yung‐Luen Yu Taiwan	28	1.7k 1.3×	701 1.2×	592 1.3×	576 1.3×	272 1.0×	80	2.6k
Chao Chen China	29	1.4k 1.1×	996 1.6×	817 1.8×	320 0.7×	427 1.5×	130	2.7k
Shuang Liu China	25	1.1k 0.9×	626 1.0×	541 1.2×	272 0.6×	207 0.7×	132	2.3k
Min Xiao China	24	1.6k 1.3×	601 1.0×	624 1.3×	208 0.5×	314 1.1×	73	3.0k
Haibin Wang China	27	1.5k 1.2×	471 0.8×	329 0.7×	180 0.4×	165 0.6×	130	2.5k
Josefa Castillo Spain	20	946 0.8×	512 0.8×	683 1.5×	331 0.8×	283 1.0×	55	2.1k
Yanqing Gong China	30	1.4k 1.1×	884 1.5×	507 1.1×	502 1.1×	150 0.5×	115	2.4k
Kaishan Tao China	31	1.5k 1.2×	921 1.5×	646 1.4×	194 0.4×	304 1.1×	108	2.9k
Masanobu Tsubaki Japan	31	1.2k 0.9×	660 1.1×	848 1.8×	206 0.5×	194 0.7×	93	2.2k

Countries citing papers authored by Minfeng Chen

Since Specialization

Citations

This map shows the geographic impact of Minfeng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minfeng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minfeng Chen more than expected).

Fields of papers citing papers by Minfeng Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minfeng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minfeng Chen. The network helps show where Minfeng Chen may publish in the future.

Co-authorship network of co-authors of Minfeng Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Minfeng Chen. A scholar is included among the top collaborators of Minfeng Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minfeng Chen. Minfeng Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Yiyi, Minfeng Chen, Junjie Lu, et al.. (2025). Anisotropic and anti-freezing cellulose hydrogel electrolyte with aligned channels stabilizing Zn metal anode. Chemical Engineering Journal. 506. 159950–159950. 8 indexed citations

Zhu, Wenhao, Yongxiang Tang, Qi Lin, et al.. (2025). Machine learning models for enhanced diagnosis and risk assessment of prostate cancer with 68Ga-PSMA-617 PET/CT. European Journal of Radiology. 186. 112063–112063. 1 indexed citations

Chen, Minfeng, Lulu Peng, Rong Yu, et al.. (2024). Analysis of anterior corneal surface shape after replacing orthokeratology lenses carrying a small base curve diameter. Frontiers in Neuroscience. 18. 1424394–1424394.

Wang, Xingming, Lin Qi, Minfeng Chen, et al.. (2024). Feasibility study of ADCs targeting TROP-2, HER2, and CD46 in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate. World Journal of Urology. 42(1). 404–404. 1 indexed citations

Mo, Miao, et al.. (2023). MIR663AHG as a competitive endogenous RNA regulating TGF‐β‐induced epithelial proliferation and epithelial–mesenchymal transition in benign prostate hyperplasia. Journal of Biochemical and Molecular Toxicology. 37(9). e23391–e23391. 7 indexed citations

Liu, Xinting, Pengqi Wang, Minfeng Chen, et al.. (2023). One‐year myopia control efficacy of cylindrical annular refractive element spectacle lenses. Acta Ophthalmologica. 101(6). 651–657. 38 indexed citations

Wang, Sheng, Maohua Huang, Minfeng Chen, et al.. (2023). Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells. Journal for ImmunoTherapy of Cancer. 11(6). e006381–e006381. 13 indexed citations

Jiang, Shuai, Hailong Hu, Zhenyu Wang, et al.. (2023). Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study. Cancer Medicine. 12(9). 10587–10596. 4 indexed citations

Deng, Lijuan, Minfeng Chen, Ming Qi, et al.. (2022). m6A modification: recent advances, anticancer targeted drug discovery and beyond. Molecular Cancer. 21(1). 52–52. 252 indexed citations breakdown →

10.

Zhu, Jiaqi, et al.. (2022). Synthesis and biological evaluation of marine natural product, Cryptoechinuline D derivatives as novel antiangiogenic agents. Bioorganic & Medicinal Chemistry Letters. 65. 128717–128717. 3 indexed citations

11.

Luo, Cong, Yushi Zhang, Mingxin Zhang, et al.. (2021). Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China. Orphanet Journal of Rare Diseases. 16(1). 299–299. 11 indexed citations

12.

Li, Zheng‐Xiang, Minfeng Chen, Jun Tang, et al.. (2021). Targeting FAPα-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis. Cancer Letters. 503. 32–42. 19 indexed citations

13.

Li, Yong, Maohua Huang, Songtao Li, et al.. (2021). 3′-Oxo-tabernaelegantine A (OTNA) selectively relaxes pulmonary arteries by inhibiting AhR. Phytomedicine. 92. 153751–153751. 7 indexed citations

14.

Chen, Minfeng, Maohua Huang, Jincheng Zhong, et al.. (2019). Targeting platelet-derived growth factor receptor β inhibits the proliferation and motility of human pterygial fibroblasts. Expert Opinion on Therapeutic Targets. 23(9). 805–817. 6 indexed citations

15.

Zhang, Jiayan, Mingqun Liu, Maohua Huang, et al.. (2019). Ginsenoside F1 promotes angiogenesis by activating the IGF-1/IGF1R pathway. Pharmacological Research. 144. 292–305. 82 indexed citations

16.

Chen, Jinbo, Meng Zhang, Yu Cui, et al.. (2018). Association Between 12 Polymorphisms of VEGF/Hypoxia/Angiogenesis Pathway Genes and Risk of Urogenital Carcinomas: A Meta-Analysis Based on Case-Control Studies. Frontiers in Physiology. 9. 715–715. 5 indexed citations

17.

Qi, Lin, Sulai Liu, Wentao Liu, et al.. (2017). CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor. BMC Cancer. 17(1). 105–105. 17 indexed citations

18.

Cui, Yu, Hequn Chen, Longfei Liu, et al.. (2016). Sexual Function after Partial Penectomy: A Prospectively Study From China. Scientific Reports. 6(1). 21862–21862. 30 indexed citations

19.

Zhang, Huihui, et al.. (2013). 5-Aza-2′-Deoxycytidine Enhances Maspin Expression and Inhibits Proliferation, Migration, and Invasion of the Bladder Cancer T24 Cell Line. Cancer Biotherapy and Radiopharmaceuticals. 28(4). 343–350. 20 indexed citations

20.

He, Jun, Yan Wang, Fei Duan, et al.. (2010). Icaritin Induces Apoptosis of HepG2 Cells via the JNK1 Signaling Pathway Independent of the Estrogen Receptor. Planta Medica. 76(16). 1834–1839. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact